Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
19 10월 2023 - 9:30PM
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“Company” or “NurExone”), a biopharmaceutical company developing
biologically-guided exosome therapy (“ExoTherapy”) for patients
with traumatic spinal cord injuries, is honored to welcome
Professor Teodoro Forcht Dagi, a renowned neurosurgeon, life
science venture capitalist and professor at the Mayo Clinic Alix
School of Medicine as well as at Queen’s University Belfast, to its
esteemed Scientific Advisory Board and Advisory Committee.
Professor Dagi’s decision to join the Scientific
Advisory Board stems from his profound belief in the regenerative
potential of exosomes for neurological diseases. According to
Professor Dagi, “The problem of neural regeneration and recovery
from neurological injury is one of the most difficult and pressing
unresolved problems in medicine. NurExone is fielding a new and
very promising approach with very powerful preliminary animal
data.”
Corporate Update
NurExone expresses its unwavering support for
Israel during these challenging times, and we stand in solidarity
with Israel’s Defense Force, families, and our employees. Our
heartfelt condolences go out to families with lost or missing loved
ones.
Despite the adversities, NurExone is fully
operational and proactive. Our staff continues to work remotely. We
extend sincere appreciation to our investors and partners for their
continued warm support.
Our commitment to growth and innovation remains
steadfast. We are dedicated to advancing our preparations for
clinical trials and expanding to other types of spinal cord injury
over time, underscoring our dedication to overcoming spinal cord
injury and enhancing the well-being of patients globally.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated, and achieved proof of principle, in
animal studies at the Technion, Israel Institute of Technology.
NurExone is translating the treatment to humans, and the company
holds an exclusive worldwide license from the Technion and Tel Aviv
University for the development and commercialization of the
technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and
DirectorPhone: +972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect
management’s current beliefs and are based on information currently
available to management as at the date hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our ability to retain key personnel, our ability to
continue investing in research and development, our ability to
secure available funding and to continue as a going concern, the
general business and economic conditions of the industries and
countries in which we operate, that the Company’s operations in
Israel will not be material disrupted by unrest in Israel and the
Israel-Hamas War, our ability to execute on our business strategy,
that there will be certain amount of demand for the Company’s
potential product, inflation will remain stable, and that the
results of our studies reflect results that can be
extrapolated.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners, the effect of the Israel-Hamas War on the Company’s
operations and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024